Truist Financial’s price objective would suggest a potential ... and hedge funds own 90.96% of the company’s stock. VertexPharmaceuticals Incorporated, a biotechnology company, engages ...
JPMorgan lowered the firm’s price target on VertexPharmaceuticals (VRTX ... s “underwhelming” Phase 2 results and views the stock as “likely to work higher in 2025 with two key launches ...